Next Article in Journal
Synthesis and Anticonvulsant Activity of Certain N-Aralkyl-N-(1-Substituted Cyclohexyl) Benzenamines
Previous Article in Journal
Rosiglitazone modifies PEDF gene expression and protein levels in the Koletsky rat choroid-RPE complex
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Preparation, Quality Control and Biodistribution Studies of two [111In]-Rituximab Immunoconjugates

1
Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS), P.O.Box: 31485-498, Karaj, Iran
2
Islamic Azad University, Science and Research Unit, P.O.Box: 14155-775, Tehran, Iran
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2008, 76(2), 151-170; https://doi.org/10.3797/scipharm.0804-07
Submission received: 6 April 2008 / Accepted: 15 May 2008 / Published: 18 May 2008

Abstract

In order to use Auger-electron therapeutic effects in CD20 antigen targeting in lymphomas, Mabthera™ (rituximab) was successively labeled with [111In]-indium chloride (185 MBq) after conjugation with freshly prepared macrocyclic bifunctional chelating agent, N-succinimidyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) and ccDTPA separately. Conjugated-Rituximab was obtained by the addition of 1 ml of a rituximab pharmaceutical solution (5 mg/ml, in phosphate buffer, pH=7.8) to a glass tube pre-coated with freshly prepared DOTA-NHS or ccDTPA (0.01-0.1 mg) at 25°C. Radiolabeling was performed at 37°C in 3h and room temperature for one hour for DOTA-conjugate and DTPA-conjugate respectively. HPLC showed an overall radiochemical purity of 97.5 and 95% for DOTA and DTPA-conjugates respectively (Specific activity =2800-5600 GBq/mM). The final isotonic 111In-rituximab complexes were checked by gel electrophoresis for radiolysis. Preliminary biodistribution studies in normal rat model performed to determine radioimmunoconjugates distribution of up to 48h.
Keywords: Rituximab; Indium-111; Biodistribution; Radiolabeling; Targetted Therapy Rituximab; Indium-111; Biodistribution; Radiolabeling; Targetted Therapy

Share and Cite

MDPI and ACS Style

JALILIAN, A.R.; SARDARI, D.; KIA, L.; ROWSHANFARZAD, P.; GAROUSI, J.; AKHLAGHI, M.; SHANEHSAZZADEH, S.; MIRZAII, M. Preparation, Quality Control and Biodistribution Studies of two [111In]-Rituximab Immunoconjugates. Sci. Pharm. 2008, 76, 151-170. https://doi.org/10.3797/scipharm.0804-07

AMA Style

JALILIAN AR, SARDARI D, KIA L, ROWSHANFARZAD P, GAROUSI J, AKHLAGHI M, SHANEHSAZZADEH S, MIRZAII M. Preparation, Quality Control and Biodistribution Studies of two [111In]-Rituximab Immunoconjugates. Scientia Pharmaceutica. 2008; 76(2):151-170. https://doi.org/10.3797/scipharm.0804-07

Chicago/Turabian Style

JALILIAN, Amir R., Darush SARDARI, Leila KIA, Pejman ROWSHANFARZAD, Javad GAROUSI, Mehdi AKHLAGHI, Saeed SHANEHSAZZADEH, and Mohammad MIRZAII. 2008. "Preparation, Quality Control and Biodistribution Studies of two [111In]-Rituximab Immunoconjugates" Scientia Pharmaceutica 76, no. 2: 151-170. https://doi.org/10.3797/scipharm.0804-07

Article Metrics

Back to TopTop